Deferasirox
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Deferasirox: From Chronic Iron Overload to HIV Infectious Disease
One-Sentence Summary
Deferasirox is an oral iron chelator used for treating chronic iron overload caused by blood transfusions (transfusion-dependent hemosiderosis). The TxGNN model predicts it may be effective for HIV infectious disease, with 0 clinical trials and 2 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic iron overload (transfusion-dependent hemosiderosis) |
| Predicted New Indication | HIV Infectious Disease |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on known pharmacological information, Deferasirox is a tridentate oral iron chelator with high selectivity for ferric iron (Fe³⁺). By depleting the intracellular labile iron pool, it reduces iron-mediated oxidative stress and downstream organ damage — a mechanism proven in conditions such as thalassemia and sickle cell disease.
Iron plays a biologically important role in HIV-1 replication. In vitro research has demonstrated that endolysosomal iron can restrict HIV-1 Tat-mediated LTR transactivation by promoting Tat protein oligomerization and increasing β-catenin expression — effectively dampening viral gene expression. Because Deferasirox depletes intracellular available iron, it could theoretically suppress HIV-1 replication through this indirect antiviral mechanism. Additional support comes from the known iron-dependence of certain viral replication enzymes, which makes iron depletion a plausible disruption strategy.
However, the mechanistic link remains firmly at the cellular biology level. The distance between in vitro iron chelation effects and clinically meaningful antiretroviral activity is substantial. No clinical trials have explored this hypothesis, and the existing literature consists only of mechanistic observations and a general drug review. The TxGNN prediction is biologically coherent but clinically unvalidated.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34550543 | 2021 | In vitro mechanistic study | Journal of Neurovirology | Endolysosomal iron restricts HIV-1 Tat-mediated LTR transactivation by promoting Tat oligomerization and upregulating β-catenin; suggests iron depletion may suppress HIV-1 transcription in neuronal cell models |
| 16529348 | 2006 | Drug review / Commentary | Journal of the American Pharmacists Association | General overview of new drugs approved around 2006, including Deferasirox at initial approval; no specific HIV efficacy data reported |
India Market Information
Deferasirox is currently not marketed in India. No product registrations are on record (total licenses: 0). Any future commercialisation pathway would require a new drug application to CDSCO.
Safety Considerations
Drug Interactions: Deferasirox has 518 documented interactions. The following major-severity interactions warrant particular attention in any HIV-positive patient population, where polypharmacy is common:
| Interacting Drug | Severity |
|---|---|
| Hydrocortisone | Major |
| Dexamethasone | Major |
| Betamethasone | Major |
| Triamcinolone | Major |
| Amphotericin B | Major |
| Amphotericin B (lipid complex) | Major |
| Amphotericin B (liposomal) | Major |
| Amphotericin B (cholesteryl sulfate) | Major |
| Acetylsalicylic acid (Aspirin) | Major |
| Mesalazine | Major |
| Balsalazide | Major |
Notable moderate interactions include Rabeprazole, Pioglitazone, Clarithromycin, Aluminum hydroxide, and Aprepitant. The high interaction burden is especially relevant for HIV patients who typically receive complex antiretroviral regimens.
Please refer to the package insert for complete warnings and contraindications. Package insert safety data (CDSCO label) was not available at time of this assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for Deferasirox in HIV infectious disease is limited to two preclinical/mechanistic publications, both at tier 3 (in vitro or commentary level), with zero registered clinical trials worldwide. While the biological hypothesis — iron chelation suppressing HIV-1 LTR transactivation via Tat oligomerization — is mechanistically coherent, it has not been tested in humans or even in animal models.
To proceed, the following is needed:
- Dedicated in vitro dose-response studies and animal model experiments confirming antiviral activity of Deferasirox at clinically relevant concentrations
- Systematic review of potential interactions with standard antiretroviral regimens (e.g., NRTIs, PIs, INSTIs), given the 518 documented DDIs
- Full MOA documentation from DrugBank to complete mechanistic rationale
- CDSCO package insert retrieval to fill critical safety gaps (warnings, contraindications)
- If preclinical data is promising: design of an exploratory hypothesis-generating Phase 1/2 study in a carefully selected patient subgroup
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.